产品封面图

NIH:OVCAR-3

收藏
  • 询价
  • 2025年12月25日
    avatar
    ATCC细胞库
    15 年金牌会员

  • 企业认证

    • 相关产品推荐更多 >

    万千商家帮你免费找货

    0 人在求购买到急需产品
    • 详细信息
    • 询价记录
    • 文献和实验
    • 技术资料
    • 年限：

      60 years

    • 生长状态：

      贴壁生长

    • 运输方式：

      冻存运输

    • 器官来源：

      卵巢

    • 物种来源：

      人

    • 是否是肿瘤细胞：

      1

    • 相关疾病：

      腺癌

    • ATCC Number：

      HTB-161™

    • 细胞类型：

      上皮细胞

    • 细胞形态：

      上皮样

    • 库存：

      大量

    Designations: NIH:OVCAR-3
    Depositors:  R Ozols, TC Hamilton
    Biosafety Level: 1
    Shipped: frozen
    Medium & Serum: See Propagation
    Growth Properties: adherent
    Organism: Homo sapiens
    Morphology: epithelial
    Source: Organ: ovary
    Disease: adenocarcinoma
    Cell Type: epithelial
    Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
    Isolation: Isolation date: 1982
    Applications: transfection host
    Receptors: androgen receptor, positive; estrogen receptor, positive; progesterone receptor, positive
    Tumorigenic: Yes
    DNA Profile (STR): Amelogenin: X
    CSF1PO: 11,12
    D13S317: 12
    D16S539: 12
    D5S818: 11,12
    D7S820: 10
    THO1: 9,9.3
    TPOX: 8
    vWA: 17
    Cytogenetic Analysis: The cell line is aneuploid human female, with chromosome counts in the sub to near-triploid range. Several normal chromosomes (N11, N13, N14, N15, N16, N17, and N22) are clearly under-represented. Many of these missing chromosomes are represented in the large number of cytogenetically altered chromosomes identified as marker chromosomes. In addition to the marker chromosomes, there are a large number of other structurally abnormal and unassignable chromosomes that are not recognized as markers. Random loss and gain of chromosomes from cell to cell are noted in the exact chromosome counts and in the analysis of the karyotypes.
    Isoenzymes: AK-1, 1
    ES-D, 1
    G6PD, B
    GLO-I, 1
    PGM1, 1
    PGM3, 1
    Age: 60 years
    Gender: female
    Ethnicity: Caucasian
    Comments: The NIH:OVCAR-3 line was established in 1982 by T.C. Hamilton, et al. from the malignant ascites of a patient with progressive adenocarcinoma of the ovary.
    Forms colonies in soft agar and has an abnormal karyotype.
    Resistant to clinically relevant concentrations of adriamycin, melphalan and cisplatin.
    Both cultured cells and xenografts exhibit androgen and estrogen receptors.
    Xenograft models have been used to show that treatment with 17 beta estradiol can induce progesterone receptors in this human ovarian carcinoma.
    NIH:OVCAR-3 is an appropriate model system in which to study drug resistance in ovarian cancer, and the presence of hormone receptors should be useful for the evaluation of hormonal therapy.
    Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: 0.01 mg/ml bovine insulin; fetal bovine serum to a final concentration of 20%.
    Temperature: 37.0°C
    Atmosphere: air, 95%; carbon dioxide (CO2), 5%
    Subculturing: Protocol: Volumes used in this protocol are for 75 sq cm flasks; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
    • Remove and discard culture medium.
    • Briefly rinse the cell layer with Ca++/Mg++ free Dulbecco's phosphate-buffered saline (D-PBS) or 0.25% (w/v) Trypsin - 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
    • Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
      Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37C to facilitate dispersal.
    • Add 2.0 to 3.0 ml of complete growth medium and aspirate cells by gently pipetting
    • Resuspend the cell pellet in fresh growth medium. Add appropriate aliquots of the cell suspension to new culture vessels.
    • Incubate cultures at 37C.

    Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended
    Medium Renewal: Every 2 to 3 days
    Preservation: Freeze medium: Complete growth medium, 95%; DMSO, 5%
    Storage temperature: liquid nitrogen vapor temperature
    Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001
    recommended serum:ATCC 30-2020
    References: 1127: Hamilton TC, et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43: 5379-5389, 1983. PubMed: 6604576
    1128: Hamilton TC, et al. Induction of progesterone receptor with 17beta-estradiol in human ovarian cancer. J. Clin. Endocrinol. Metab. 59: 561-563, 1984. PubMed: 6746867
    22949: Rogan AM, et al. Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224: 994-996, 1984. PubMed: 6372095
    23051: Hamilton TC, et al. Characterization of a xenograft model of human ovarian carcinoma which produces ascites and intraabdominal carcinomatosis in mice. Cancer Res. 44: 5286-5290, 1984. PubMed: 6333272
    23052: Green JA, et al. Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by glutathione depletion. Cancer Res. 44: 5427-5431, 1984. PubMed: 6488194
    23100: Caffrey PB, Frenkel GD. Selenite cytotoxicity in drug resistant and nonresistant human ovarian tumor cells. Cancer Res. 52: 4812-4816, 1992. PubMed: 1511444
    23164: Hamilton TC, et al. Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches. Semin. Oncol. 11: 285-298, 1984. PubMed: 6385258
    23329: Godwin AK, et al. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. Natl. Acad. Sci. USA 89: 3070-3074, 1992. PubMed: 1348364
    32582: Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Natl. Acad. Sci. USA 93: 136-140, 1996. PubMed: 8552591
    32690: Omelyanenko V, et al. HPMA copolymer-anticancer drug-OV-TL16 antibody conjugates. II. Processing in epithelial ovarian carcinoma cells in vitro. Int. J. Cancer 75: 600-608, 1998. PubMed: 9466663

    风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。

    • 作者
    • 内容
    • 询问日期
    图标文献和实验
    相关实验

    • NIH 最新研究揭示微生物异位与 HIV 感染者治疗后的免疫重建规律

      背景介绍当前，尽管联合抗逆转录病毒疗法（combined antiretroviral therapy，cART）在治疗艾滋病毒感染方面取得了巨大进展，但经治疗感染者的非艾滋病发病率和死亡率仍然高于未受感染的人，这提示了某些感染者免疫系统的重建可能是不完全的。前期研究也表明，CD4 T 细胞重建不良提示着较差的长期临床预后。虽然说炎症和 CD4 T 细胞重建明显相关，比如说，从长远来看，炎症和 CD4 T 细胞重建之间的关系显然是负的，但炎症仍然被认为是临床预后的独立预测因素。HIV 感染者中

    • 生物芯片实验手册（NIH）

        OVERVIEW Fluorescent cDNA microarray technology is useful for making estimates of the abundance of particular messages relative to a designated source of mRNA that serves as a reference point. Commercial support of this technology

    • NIH3T3 TK-是什么意思

      NIH3T3细胞中本身是没有TK的，1981年Scolnick利用lambda载体把胸腺嘧啶激酶（TK）转入NIH3T3细胞，构建成NIH3T3 TK细胞，所以细胞分为NIH3T3 TK＋和NIH3T3 TK-两种细胞，在Scolnick认为NIH3T3就是NIH3T3（TK－）。 他做转染细胞的基础是基于1969年Todaro的实验。 具体内容参看建株文献：J Virol.1981 September； 39（3）： 935–944

    查看更多相关实验 >
    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    NIH:OVCAR-3人卵巢癌细胞
    ¥2200
    上海钰博生物科技有限公司
    2025年07月14日询价
    NIH:OVCAR-3细胞、卵巢癌细胞
    询价
    上海康朗生物科技有限公司
    2025年07月10日询价
    NIH:OVCAR-3人卵巢癌腺癌细胞
    询价
    上海复祥生物科技有限公司
    2025年11月24日询价
    人卵巢癌腺癌细胞；NIH:OVCAR-3
    ¥800
    上海沪震实业有限公司
    2025年07月13日询价
    A549
    询价
    ATCC细胞库
    2026年01月09日询价
    NIH:OVCAR-3
    询价